Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,747Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M1,747EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.7PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M32,400,032ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

XBI is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dubuc, PhilippeSenior Officer 2016-04-08Buy1,700$1.992603.02view
Dubuc, PhilippeSenior Officer 2016-04-08Buy3,300$22589.5view
PAMPLIN, Ann-Marie MichelleDeemed Insider - 6 Months before becoming Insider 2016-04-08Buy10,000$0.1535760view
Williams, Allan WilliamSenior Officer 2016-04-08Buy108,500$0.1148800view
Stefura, Naomi MarieSenior Officer 2016-04-08Sell4,200$14.6268.42view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell800$20.78158.85view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell400$20.77158.98view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell300$20.75159.23view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell100$20.72159.6view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell900$20.7159.86view

Quarterly/Annual Reports about XBI:

    News about XBI:

    Articles On GuruFocus.com
    Value Investing in BioPharma Nov 18 2015 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    Is XBI Heading Back to Where It Started in April? Apr 28 2016
    Opportunities For Xtandi, Medivation’s Key Drug Apr 28 2016
    Energy-Related Stocks Rose after FOMC Decision Apr 27 2016
    Trader's Notebook: Responding to the Move in Dollar Futures Apr 25 2016
    Trader's Notebook: Searching for Bullish Excess in the Banks Apr 22 2016
    Rising Dollar Offsets Crude Prices as Major SPDR Indexes Fall Apr 21 2016
    XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study Apr 21 2016
    How Does XBI Compare to Its 100-Day Moving Average? Apr 21 2016
    XBI Mid-Caps: Medivation Rose after Rejecting Sanofi’s Takeover Bid Apr 20 2016
    SPDR Indexes across Energy and Gold Rise on Increase in Commodities Apr 19 2016
    What Do Analysts Recommend for Medivation? Apr 19 2016
    Return Of The Mack: This Biotech ETF Is Back Apr 19 2016
    Recovery in Crude Prices Lifts Energy and Healthcare SPDR Indexes Apr 18 2016
    US Dollar Is Strong despite Inflation Releasing below Forecast Apr 14 2016
    Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue Apr 14 2016
    Large-Cap News: Edwards Surged on SAPIENT 3 TAVR Data Apr 11 2016
    Among Biotechnology ETFs, XBI Dominated the 1st Week of April Apr 11 2016
    XBI Mid Caps: Alnylam to Present at Needham Healthcare Conference Apr 08 2016
    Incyte Continues Its Growth Spree in 2015 Apr 07 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)